Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioma 2Glioblastoma 2Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Head and Neck Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Central Nervous System Neoplasms 1Carcinoma, Squamous Cell 1

Interventions

Bevacizumab 3ribociclib 2Temozolomide 2Radiotherapy 2Radiation 2Panobinostat 2pembrolizumab 1dipinacoline glutamate 1dinutuximab 1cemiplimab 1adavosertib 1abemaciclib 1Vorinostat 1Valproic Acid 1Re-Irradiation 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Nivolumab 1Maintenance 1Irinotecan 1Granulocyte-Macrophage Colony-Stimulating Factor 1Everolimus 1Erlotinib Hydrochloride 1Congresses as Topic 1Chemotherapy, Adjuvant 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Diffuse Intrinsic Pontine Glioma × Re-Irradiation × Clear all
NCT03690869 2025-04-08

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

Regeneron Pharmaceuticals

Phase 1/2 Terminated
57 enrolled 31 charts
CNS

Diffuse Intrinsic Pontine Glioma, Glioma, Recurrence, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡